Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Ex ...

Core Insights - Tharimmune, Inc. has appointed Jill Sommers and William Wiley to its Board of Directors to enhance governance as the company advances its Canton Network infrastructure [1][2] Group 1: Board Appointments - Jill Sommers brings nearly three decades of experience in derivatives and financial markets, having served as a Commissioner of the U.S. Commodity Futures Trading Commission (CFTC) and held senior roles in regulatory affairs [2][3] - William Wiley has extensive capital markets experience and has led complex global operations, currently serving as Head of the Equities and Latency Sensitive Business Unit at DRW [3][4] Group 2: Strategic Vision - The company aims to modernize financial infrastructure through its digital asset treasury strategy, leveraging Canton Coin to support the Canton Network [2][4] - Tharimmune intends to invest in applications built on the Canton Network to enhance institutional utility and adoption across capital markets [4] Group 3: Company Overview - Tharimmune is the first publicly traded company to utilize Canton Coin and support the Canton Network, focusing on advancing institutional blockchain adoption and the digitization of financial markets [5]

Summary of Tharimmune, Inc. Special Meeting Company Overview - **Company**: Tharimmune, Inc. (NasdaqCM:THAR) - **Meeting Date**: January 30, 2026 - **Key Participants**: Mark Wendland (CEO), Jacob Asbury (CFO), Francis H. Bird (Inspector of Election) Key Proposals and Votes 1. **Election of Directors** - Two directors nominated: Jill E. Summers and William Wiley - Each nominee's term expires at the next annual meeting - Requires a plurality of votes to be elected - **Outcome**: Approved [12] 2. **Issuance of Shares for Strategic Advisor Warrants** - Proposal to approve issuance of shares upon exercise of Strategic Advisor Warrants - Requires majority vote for approval - **Outcome**: Approved [12] 3. **Issuance of Shares for Cryptocurrency Pre-Funded Warrants** - Proposal related to shares issued in connection with a private placement on November 3, 2025 - Requires majority vote for approval - **Outcome**: Approved [13] 4. **Issuance of Restricted Stock Units to Clear Street, LLC** - Proposal for issuance of restricted stock units and common stock upon settlement - Requires majority vote for approval - **Outcome**: Approved [13] 5. **Amendment to the 2023 Omnibus Equity Incentive Plan** - Proposal to increase the number of shares available for issuance by 7 million shares - Requires majority vote for approval - **Outcome**: Approved [13] 6. **Adjournment of the Meeting** - Proposal to approve adjournments if necessary for further solicitation of votes - Requires majority vote for approval - **Outcome**: Approved [13] Additional Information - **Voting Process**: Shareholders were informed that abstentions would count as votes against the proposals [5][9] - **Quorum**: A quorum of shareholders was present, allowing the meeting to proceed lawfully [3] - **No Questions Submitted**: There were no questions from shareholders during the meeting [11] Conclusion - The special meeting concluded with all proposals being approved, indicating strong shareholder support for the company's strategic initiatives and governance [14]

Core Insights - Tharimmune, Inc. has been approved to operate as a Super Validator on the Canton Network, enhancing its digital asset treasury strategy through contributions to the network [1][5]. Group 1: Company Developments - Tharimmune is the first publicly traded company to utilize Canton Coin to support the Canton Network's digitization of traditional financial markets [1][6]. - The company plans to provide quarterly research on onchain analytics, community development, governance, and tokenomics updates, along with hosting public webinars to engage ecosystem participants [2]. - Tharimmune aims to invest in applications on the Canton Network to promote institutional utility and adoption in capital markets [5]. Group 2: Network and Market Impact - The Canton Network processes over 700,000 daily transactions, amounting to $9 trillion in monthly transaction volume, highlighting its critical role in transforming global financial infrastructure [3]. - The network is increasingly favored by global financial institutions for its programmable privacy features, allowing for instantaneous settlement while maintaining discretion for authorized parties [4]. - The Canton Network's capabilities are expected to unlock greater liquidity for financial markets through atomic settlement [3].

Company Overview - Tharimmune, Inc. (THAR) is a pre-revenue biotech research and development firm with no long-term debt [1] - The company reported annual expenses of $10.3 million and $7.6 million in unspecified revenue [1] Investment Strategy - The investment approach focuses on a diversified portfolio including low-cost index funds, U.S. T-Bills/Treasuries, investment real estate, and a small percentage of individual stocks [1] - Individual stocks are selected for long-term growth potential or to provide higher income compared to real estate investments [1] Current Holdings - Current individual stock holdings include AMZN, TSMC, EPD, TROW, and BMNR, with a long position in all except TROW, where covered calls are consistently sold [1] Analyst's Position - The analyst holds a beneficial long position in THAR through stock ownership, options, or other derivatives [1] - The article reflects the analyst's personal opinions and is not compensated beyond contributions to Seeking Alpha [1]

Core Viewpoint - Tharimmune, Inc. has successfully closed a registered direct offering, raising approximately $55 million to support its digital asset treasury strategy and general corporate purposes [2][3]. Group 1: Offering Details - The offering included the issuance of 1,800,000 shares of common stock at a price of $2.92 per share and pre-funded warrants to purchase up to 17,000,000 shares at a price of $2.9199 per warrant [1][2]. - Clear Street acted as the sole bookrunning manager for the offering, with legal counsel provided by Paul Hastings LLP for Clear Street and Reed Smith for Tharimmune [3]. Group 2: Company Overview - Tharimmune, Inc. is the first publicly traded company to utilize Canton Coin, aiming to enhance institutional blockchain adoption and the digitization of financial markets [6]. - The company operates a differentiated digital asset treasury strategy by participating in the Canton Network, which is a secure blockchain hosting trillions in assets [3][6].

Core Viewpoint - Tharimmune, Inc. has completed a $55 million underwritten public offering, issuing 1.8 million shares at $2.92 per share, along with up to 17 million pre-funded warrants [1] Group 1: Financial Details - The company raised funds through the issuance of 1.8 million shares priced at $2.92 each [1] - The total amount raised from the offering is $55 million [1] Group 2: Use of Proceeds - The funds will be used to continue expanding and developing its digital asset treasury strategy centered around the Canton Network [1] - Additionally, the proceeds will support general operational expenses [1] Group 3: Company Position - Tharimmune is the first publicly traded company to utilize Canton Coin and participate in the Canton Network [1]

Core Viewpoint - Tharimmune, Inc. has announced a $55 million registered offering to support its digital asset treasury strategy leveraging the Canton Network, which aims to digitize traditional financial markets [1][2]. Group 1: Offering Details - The offering includes the issuance of 1,800,000 shares of common stock at a price of $2.92 per share and pre-funded warrants to purchase up to 17,000,000 shares at a price of $2.9199 per warrant [2]. - The offering is expected to close on or about January 21, 2026, pending customary closing conditions [2]. Group 2: Company Background - Tharimmune, Inc. is the first publicly traded company to utilize Canton Coin and support the Canton Network, focusing on institutional blockchain adoption and the digitization of financial markets [6]. - The company also engages in clinical-stage biotech research and development [6]. Group 3: Underwriting and Registration - Clear Street is acting as the sole bookrunner for the offering [3]. - The securities are being offered under a shelf registration statement filed with the SEC on January 9, 2026, which became effective on January 16, 2026 [4].

Core Insights - Tharimmune, Inc. is the first publicly traded company to utilize Canton Coin to enhance the Canton Network's capability in digitizing traditional financial markets [1][5] - The partnership between DTCC and Digital Asset Holdings aims to tokenize U.S. Treasury securities, representing a significant advancement in blockchain adoption within institutional finance [2][3] Group 1: Institutional Adoption of Blockchain - The collaboration with DTCC signifies a structural shift towards on-chain financial systems, with over $30 trillion in U.S. Treasury assets currently held by DTCC, presenting a unique opportunity for treasury and repo transactions on-chain [2][4] - The Canton Network offers programmable privacy, allowing market participants to achieve instantaneous settlement while maintaining confidentiality regarding trade identities, which is crucial for institutional adoption [3][4] Group 2: Transaction Volume and Growth Strategy - The Canton Network has achieved a monthly transaction volume of $9 trillion, with over 700,000 daily transactions, indicating a robust and growing ecosystem [4] - Tharimmune's digital asset treasury strategy, initiated with a $545 million private placement, aims to support the Canton Network's expansion and long-term development, including acquiring Canton Coin and pursuing roles as a Super Validator [4]

Core Viewpoint - Tharimmune, Inc. has appointed Jacob Asbury as Chief Financial Officer to enhance its financial strategy and operations, particularly in relation to its digital asset treasury strategy leveraging Canton Coin [1][3]. Group 1: Company Leadership and Strategy - Jacob Asbury brings nearly two decades of financial leadership experience, having previously served as CFO at Clear Street Group and other firms, which positions him well to oversee Tharimmune's financial operations [2]. - The appointment of Asbury is seen as a commitment to advancing the Canton Network's infrastructure and enhancing shareholder value through innovative financial operations [3]. - Tharimmune's digital asset treasury strategy, established in November 2025, aims to create value by acquiring Canton Coin and operating as a Super Validator, thereby investing in applications that promote institutional adoption in capital markets [3]. Group 2: Company Overview - Tharimmune, Inc. is the first publicly traded company to utilize Canton Coin, supporting the Canton Network's goal of digitizing financial markets and promoting blockchain adoption [4]. - In addition to its focus on digital assets, Tharimmune is also engaged in clinical-stage biotech research and development, indicating a diversified business model [4].